Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013 (2013), Article ID 174168, 8 pages
http://dx.doi.org/10.1155/2013/174168
Research Article

Attenuation of Myocardial Injury by HMGB1 Blockade during Ischemia/Reperfusion Is Toll-Like Receptor 2-Dependent

1Department of Anaesthesia, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Goethe University, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany
2Department of Trauma Surgery, University Hospital Gießen and Marburg GmbH, 35043 Marburg, Germany
3Institute for Microbiology and Hygiene, Charité Medical Center, 12203 Berlin, Germany

Received 29 August 2013; Revised 23 October 2013; Accepted 4 November 2013

Academic Editor: Stefanie B. Flohé

Copyright © 2013 Jan Mersmann et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Arslan, M. B. Smeets, L. A. J. O'Neill et al., “Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-toll-like receptor-2 antibody,” Circulation, vol. 121, no. 1, pp. 80–90, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Ha, Y. Hu, L. Liu et al., “TLR2 ligands induce cardioprotection against ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism,” Cardiovascular Research, vol. 87, no. 4, pp. 694–703, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Mersmann, R. Berkels, P. Zacharowski et al., “Preconditioning by toll-like receptor 2 agonist Pam3CSK4 reduces CXCL1-dependent leukocyte recruitment in murine myocardial ischemia/reperfusion injury,” Critical Care Medicine, vol. 38, no. 3, pp. 903–909, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Mersmann, A. Koch, N. Tran et al., “Toll-like receptor 2 signaling triggers fatal arrhythmias upon myocardial ischemia-reperfusion,” Critical Care Medicine, vol. 38, no. 10, pp. 1927–1932, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Mersmann, N. Tran, K. Latsch et al., “Akt or phosphoinositide-3-kinase inhibition reverses cardio-protection in Toll-like receptor 2 deficient mice,” Resuscitation, vol. 11, pp. 1404–1410, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Müller, P. Scaffidi, B. Degryse et al., “The double life of HMGB1 chromatin protein: architectural factor and extracellular signal,” The EMBO Journal, vol. 20, no. 16, pp. 4337–4340, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Tang, R. Kang, K. M. Livesey et al., “Endogenous HMGB1 regulates autophagy,” Journal of Cell Biology, vol. 190, no. 5, pp. 881–892, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Scaffidi, T. Misteli, and M. E. Bianchi, “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,” Nature, vol. 418, no. 6894, pp. 191–195, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Tang, Y. Shi, R. Kang et al., “Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1,” Journal of Leukocyte Biology, vol. 81, no. 3, pp. 741–747, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. U. Andersson, H. Wang, K. Palmblad et al., “High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes,” Journal of Experimental Medicine, vol. 192, no. 4, pp. 565–570, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Wang, O. Bloom, M. Zhang et al., “HMG-1 as a late mediator of endotoxin lethality in mice,” Science, vol. 285, no. 5425, pp. 248–251, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. M.-F. Tsan, “Heat shock proteins and high mobility group box 1 protein lack cytokine function,” Journal of leukocyte biology, vol. 89, no. 6, pp. 847–853, 2011. View at Google Scholar · View at Scopus
  13. M. Andrassy, H. C. Volz, J. C. Igwe et al., “High-mobility group box-1 in ischemia-reperfusion injury of the heart,” Circulation, vol. 117, no. 25, pp. 3216–3226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. R. Kokkola, Å. Andersson, G. Mullins et al., “RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages,” Scandinavian Journal of Immunology, vol. 61, no. 1, pp. 1–9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Taguchi, D. C. Blood, G. Del Toro et al., “Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases,” Nature, vol. 405, no. 6784, pp. 354–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. J. S. Park, D. Svetkauskaite, Q. He et al., “Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein,” The Journal of Biological Chemistry, vol. 279, no. 9, pp. 7370–7377, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Tian, A. M. Avalos, S.-Y. Mao et al., “Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE,” Nature Immunology, vol. 8, no. 5, pp. 487–496, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. S. P. Jong, F. Gamboni-Robertson, Q. He et al., “High mobility group box 1 protein interacts with multiple Toll-like receptors,” American Journal of Physiology: Cell Physiology, vol. 290, no. 3, pp. C917–C924, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Yu, H. Wang, A. Ding et al., “HMGB1 signals through toll-like receptor (TLR) 4 and TLR2,” Shock, vol. 26, no. 2, pp. 174–179, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. F. Limana, A. Germani, A. Zacheo et al., “Exogenous high-mobility group box 1 protein induces myocardial regeneration after infarction via enhanced cardiac C-kit+ cell proliferation and differentiation,” Circulation research, vol. 97, no. 8, pp. e73–83, 2005. View at Google Scholar · View at Scopus
  21. T. Kitahara, Y. Takeishi, M. Harada et al., “High-mobility group box 1 restores cardiac function after myocardial infarction in transgenic mice,” Cardiovascular Research, vol. 80, no. 1, pp. 40–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. K. Takahashi, S. Fukushima, K. Yamahara et al., “Modulated inflammation by injection of high-mobility group box 1 recovers post-infarction chronically failing heart,” Circulation, vol. 14, supplement 1, pp. S106–S114, 2008. View at Google Scholar
  23. N. W. J. Schröder, C. Hermann, L. Hamann, U. B. Göbel, T. Hartung, and R. R. Schumann, “High frequency of polymorphism Arg753Gln of the Toll-like receptor-2 gene detected by a novel allele-specific PCR,” Journal of Molecular Medicine, vol. 81, no. 6, pp. 368–372, 2003. View at Google Scholar · View at Scopus
  24. L. Hamann, A. Gomma, N. W. J. Schröder et al., “A frequent toll-like receptor (TLR)-2 polymorphism is a risk factor for coronary restenosis,” Journal of Molecular Medicine, vol. 83, no. 6, pp. 478–485, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Mersmann, N. Tran, P. A. Zacharowski, D. Grotemeyer, and K. Zacharowski, “Rosiglitazone is cardioprotective in a murine model of myocardial i/r,” Shock, vol. 30, no. 1, pp. 64–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Mersmann, K. Habeck, K. Latsch et al., “Left ventricular dilation in toll-like receptor 2 deficient mice after myocardial ischemia/reperfusion through defective scar formation,” Basic Research in Cardiology, vol. 106, no. 1, pp. 89–98, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Koch, L. Hamann, M. Schott et al., “Genetic variation of TLR4 influences immunoendocrine stress response: an observational study in cardiac surgical patients,” Critical Care, vol. 2, pp. R109–R109, 2011. View at Google Scholar
  28. L. Hamann, A. Hamprecht, A. Gomma, and R. R. Schumann, “Rapid and inexpensive real-time PCR for genotyping functional polymorphisms within the Toll-like receptor -2, -4, and -9 genes,” Journal of Immunological Methods, vol. 285, no. 2, pp. 281–291, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Vinten-Johansen, “Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury,” Cardiovascular Research, vol. 61, no. 3, pp. 481–497, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. S. M. Robert, H. Sjodin, M. P. Fink, and R. K. Aneja, “Preconditioning with high mobility group Box 1 (HMGB1) induces lipoteichoic acid (LTA) tolerance,” Journal of Immunotherapy, vol. 33, no. 7, pp. 663–671, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Erridge, “Endogenous ligands of TLR2 and TLR4: agonists or assistants?” Journal of Leukocyte Biology, vol. 87, no. 6, pp. 989–999, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. J. H. Youn, Y. J. Oh, E. S. Kim, J. E. Choi, and J.-S. Shin, “High mobility group box 1 protein binding to lipopolysaccharide facilitates transfer of lipopolysaccharide to CD14 and enhances lipopolysaccharide-mediated TNF-α production in human monocytes,” Journal of Immunology, vol. 180, no. 7, pp. 5067–5074, 2008. View at Google Scholar · View at Scopus
  33. Y. Sha, J. Zmijewski, Z. Xu, and E. Abraham, “HMGB1 develops enhanced proinflammatory activity by binding to cytokines,” Journal of Immunology, vol. 180, no. 4, pp. 2531–2537, 2008. View at Google Scholar · View at Scopus
  34. H. S. Hreggvidsdottir, T. Östberg, H. Wähämaa et al., “The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 655–662, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. V. Sørensen, S. Pedersen, R. Møgelvang, J. Skov-Jensen, and A. Flyvbjerg, “Plasma high-mobility group box 1 levels predict mortality after ST-segment elevation myocardial infarction,” JACC: Cardiovascular Interventions, vol. 4, no. 3, pp. 281–286, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Andrassy, H. C. Volz, N. Riedle et al., “HMGB1 as a predictor of infarct transmurality and functional recovery in patients with myocardial infarction,” Journal of Internal Medicine, vol. 270, no. 3, pp. 245–253, 2011. View at Publisher · View at Google Scholar · View at Scopus